JP2005516988A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516988A5
JP2005516988A5 JP2003565420A JP2003565420A JP2005516988A5 JP 2005516988 A5 JP2005516988 A5 JP 2005516988A5 JP 2003565420 A JP2003565420 A JP 2003565420A JP 2003565420 A JP2003565420 A JP 2003565420A JP 2005516988 A5 JP2005516988 A5 JP 2005516988A5
Authority
JP
Japan
Prior art keywords
pharmaceutical combination
cells
pharmaceutical
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516988A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/003513 external-priority patent/WO2003065994A2/en
Publication of JP2005516988A publication Critical patent/JP2005516988A/ja
Publication of JP2005516988A5 publication Critical patent/JP2005516988A5/ja
Pending legal-status Critical Current

Links

JP2003565420A 2002-02-07 2003-02-07 シュヴァン細胞およびホスホジエステラーゼインヒビターに基づく治療 Pending JP2005516988A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35430602P 2002-02-07 2002-02-07
PCT/US2003/003513 WO2003065994A2 (en) 2002-02-07 2003-02-07 Schwann cell and phosphodiesterase inhibitors based therapy

Publications (2)

Publication Number Publication Date
JP2005516988A JP2005516988A (ja) 2005-06-09
JP2005516988A5 true JP2005516988A5 (https=) 2006-06-29

Family

ID=27734351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565420A Pending JP2005516988A (ja) 2002-02-07 2003-02-07 シュヴァン細胞およびホスホジエステラーゼインヒビターに基づく治療

Country Status (7)

Country Link
US (2) US20030220280A1 (https=)
EP (1) EP1482916A4 (https=)
JP (1) JP2005516988A (https=)
KR (1) KR20040101220A (https=)
AU (1) AU2003210869A1 (https=)
CA (1) CA2476275A1 (https=)
WO (1) WO2003065994A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
JP3886346B2 (ja) * 2001-06-22 2007-02-28 サンバイオ,インコーポレイティド 骨髄間質細胞由来Schwann細胞を含む神経再生用医薬組成物
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
ES2412481T3 (es) * 2006-05-19 2013-07-11 Dart Neuroscience Llc Inhibidores de la fosfodiesterasa 4 para la rehabilitación motora
US7811549B2 (en) 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
KR20080007800A (ko) * 2006-07-18 2008-01-23 한훈 씨디34 음성 및 씨디45 양성의 제대혈 유래 줄기세포를이용한 척수 손상 세포 치료제 조성물
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
WO2009092516A2 (en) * 2008-01-22 2009-07-30 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
WO2009111649A2 (en) * 2008-03-05 2009-09-11 Regenerative Research Foundation Methods and compositions for delivery of exogenous factors to nervous system sites
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2802896C (en) 2010-07-01 2021-05-11 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US134821A (en) * 1873-01-14 Improvement in row-locks
US6104754A (en) * 1995-03-15 2000-08-15 Kabushiki Kaisha Toshiba Moving picture coding and/or decoding systems, and variable-length coding and/or decoding system
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US6002802A (en) * 1995-10-27 1999-12-14 Kabushiki Kaisha Toshiba Video encoding and decoding apparatus
JP3681835B2 (ja) * 1995-12-27 2005-08-10 三菱電機株式会社 画像符号化装置及び画像復号化装置及び符号化・復号化システム
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US6266370B1 (en) * 1996-09-03 2001-07-24 Nippon Telegraph And Telephone Corporation Brightness-variation compensation method and coding/decoding apparatus for moving pictures
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
CA2320177A1 (en) * 1998-02-13 1999-08-19 Quvis, Inc. Apparatus and method for optimized compression of interlaced motion images
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
US6459773B1 (en) * 2000-05-05 2002-10-01 Lucent Technologies Inc. System to pre-qualify copper subscriber loops for high bandwidth access service using subscriber or network generated tones
EP1343528A2 (en) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US6524854B1 (en) * 2001-09-11 2003-02-25 Isis Pharmaceuticals, Inc. Antisense inhibition of PKA regulatory subunit RII alpha expression

Similar Documents

Publication Publication Date Title
JP2005516988A5 (https=)
AU715380B2 (en) Pyrazolopyrimidines for treatment of neuronal and other disorders
RU2409576C2 (ru) Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
RU2417994C2 (ru) Производные пиразина, полезные в качестве антагонистов аденозинового рецептора
US12240833B2 (en) Pyridazinone compounds and uses thereof
RU2379292C2 (ru) Производные пиразола в качестве ингибиторов фосфодиэстеразы 4
RU2009133794A (ru) Гербициды на основе замещенного n-оксида пиридина
RU2003124651A (ru) Производные триазоло[4,5-d]пиримидина и их применение в качестве антагонистов пуринергического рецептора
RU2004106783A (ru) Производные 4-амино-6-фенилпирроло[2, 3] пиримидина
JP2007503443A5 (https=)
US5175165A (en) Antiviral combinations and compounds therefor
AU2008276451A1 (en) Treatments of B-cell proliferative disorders
RU2001107897A (ru) Фармацевтическая композиция для лечения гепатита
MX2011000026A (es) Inhibidores de proteina cinasas.
RU2003124653A (ru) Производные пурина в качестве антагонистов пуринергических рецепторов
US20130040972A1 (en) USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA
JP2018513190A5 (https=)
JP2005516924A5 (https=)
JPS6051112A (ja) 抗ウイルス配合組成物
JP2004525183A5 (https=)
JP2003506438A5 (https=)
KR950702551A (ko) 염증 및 면역 질환의 치료용 2,5-디아릴 테트라히드로티오펜, 2,5-디아릴 테트라히드로푸란 및 그 유사물(2,5-diaryl tetrahydro-thiophene, furans and analogs for the treatment of inflamimatory and immune disorders)
CA2553704A1 (en) Substituted benzimidazoles and their use for inducing apoptosis
US20060079540A1 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
JP2003516994A5 (https=)